表紙
市場調査レポート

肥満症:世界の医薬品予測と市場分析

PharmaPoint: Obesity - Global Drug Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 296457
出版日 ページ情報 英文 542 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
肥満症:世界の医薬品予測と市場分析 PharmaPoint: Obesity - Global Drug Forecast and Market Analysis to 2022
出版日: 2013年10月31日 ページ情報: 英文 542 Pages
概要

長い間休眠状態にあった肥満症市場は、複数の経路を同時に標的としたり食欲を抑制したりする併用療法や、新たな作用機序を有する分子実体といったいくつかの新治療法の登場により、復活を遂げています。パイプラインの最終段階にある薬剤の増加により、この市場は今後10年間で大きく成長する事が見込まれます。この成長の主な促進要因は、薬理的治療が必要な過体重および肥満人口の増加、医師による疾患の進行を抑えるための予防目的の薬理的治療の増加などがあり、これらの因子は、とりわけ経済成長著しい新興市場におけるブランド医薬品の需要を促進するでしょう。

当レポートでは、肥満症の概要や肥満症治療市場の収益、年間の治療費と利用パターンデータ、競合評価、市場の特性、アンメットニーズ、パイプラインの分析、現在および将来市場の分析などを提供しており、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因と病態生理学
  • 症状

第4章 疫学

  • 疾患の概要
  • リスク因子と併存症
  • 世界の動向
  • 予測手法
  • 過体重の疫学予測
  • 肥満の疫学予測
  • 肥満クラス1の疫学予測
  • 肥満クラス2の疫学予測
  • 肥満クラス3の疫学予測
  • 成人の過体重および肥満における共存症の疫学予測
  • 議論

第5章 疾患管理

  • 治療概要
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • ブラジル
  • カナダ

第6章 競合評価

  • 概要
  • 戦略的競合評価
  • 製品プロファイル:薬剤
  • 製品プロファイル:医療機器 - 人工膨満装置
  • 製品プロファイル:医療機器 - 内視鏡外科装置
  • 製品プロファイル:医療機器 - 胃電気刺激装置
  • 製品プロファイル:医療機器 - 吸収障害装置
  • 製品プロファイル:医療機器 - 神経細胞ブロック技術
  • 製品プロファイル:医療機器 - 胃拘束装置

第7章 機会とアンメットニーズ

  • 概要
  • 平均10%以上の減量を可能とする薬剤
  • 安全性と忍容性の高い薬剤
  • 償還
  • 医師の教育
  • 薬剤による治療率の向上
  • ガイドラインの改善
  • 診断へのアプローチの改善

第8章 パイプライン評価

  • 概要
  • 治験マッピング
  • 治験の段階と状況
  • 有望な薬剤と臨床開発
  • 人工膨満装置
  • 開発中の有望な脳深部刺激装置
  • 有望な内視鏡外科装置
  • 開発中の有望な吸収障害装置
  • 開発中の有望な胃拘束装置

第9章 現在および将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル:製薬およびバイオテクノロジー企業
  • 企業プロファイル:装置企業

第10章 市場の見通し

  • 世界市場
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • ブラジル
  • カナダ

第11章 付録

目次
Product Code: GDHC50PIDR

After a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients. These factors will be particularly true in the emerging markets where uptake of branded drugs will increase due to rapid economic growth.

Highlights

Key Questions Answered

  • The Obesity market is marked by the presence of several key unmet needs. What are these main unmet needs? Will the drugs under development fulfil these unmet needs? How do physicians and payers perceive these pipeline and currently marketed drugs?
  • Only one older generation drug with modest efficacy had been available until the recent arrival of two new therapies that could potentially change the prescribing landscape. Will these drugs make a significant impact on the Obesity market? Which drugs are used off-label for the treatment of obesity?
  • The diagnosed prevalence of Obesity in the world skyrocketed in the past 10 years and will continue increasing at a fast pace. How will epidemiological changes impact the growth of the future market? How does the burden of comorbidities associated with overweight and obesity impact the treatment algorithm?

Key Findings

  • The main driver of growth of the Obesity market will be the growing population of overweight and obese individuals needing pharmacological intervention and the subsequent rise in the obesity-related comorbidities to put obesity at the forefront of the medical community as a veritable disease with life-threatening implications.
  • The second largest driver will be the physicians' efforts to delay disease progression through the use of combination therapies and novel branded drugs with greater efficacy and better safety profiles.
  • To ensure patients gain access to novel, life-saving therapies, companies need to establish an agreement with third party payers to beholden them to a larger share of the responsibility for drug therapy reimbursement.
  • To date, no drug has achieved blockbuster status. This unmet need presents a large opportunity for drug developers to capture an unoccupied market space.

Scope

  • Overview of Obesity, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized Obesity therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the Obesity therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global Obesity therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global Obesity therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Obesity therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global Obesity therapeutics market from 2012-2022.
  • Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
  • 3.2. Symptoms

4. Epidemiology

  • 4.1. Disease Overview
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
  • 4.4. Forecast Methodology
  • 4.5. Epidemiology Forecast of Overweight (2012-2022)
  • 4.6. Epidemiology Forecast of Obesity (2012-2022)
  • 4.7. Epidemiology Forecast of Obesity Class I (2012-2022)
  • 4.8. Epidemiology Forecast of Obesity Class II (2012-2022)
  • 4.9. Epidemiology Forecast of Obesity Class III (2012-2022)
  • 4.10. Epidemiology Forecast of Comorbidities among Adults with Overweight/Obesity (2012 and 2022)
  • 4.11. Discussion

5. Disease Management

  • 5.1. Treatment Overview
  • 5.2. US
  • 5.3. France
  • 5.4. Germany
  • 5.5. Italy
  • 5.6. Spain
  • 5.7. UK
  • 5.8. Japan
  • 5.9. Brazil
  • 5.10. Canada

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitor Assessment
  • 6.3. Product Profiles: Drugs
  • 6.4. Product Profiles: Medical Devices - Artifical Fulness Devices
  • 6.5. Product Profiles: Medical Devices - Endoscopic Surgical Devices
  • 6.6. Product Profiles: Medical Devices - Gastric Electrical Stimulation
  • 6.7. Product Profiles: Medical Devices - Malabsorption Devices
  • 6.8. Product Profiles: Medical Devices - Neuronal Blocking Technology
  • 6.9. Product Profiles: Medical Devices - Restrictive Devices

7. Opportunity and Unmet Need

  • 7.1. Overview
  • 7.2. A Drug with Greater Than 10% Average Weight Loss
  • 7.3. A Drug with Increased Safety and Tolerability
  • 7.4. Reimbursement by Private and Public Payers
  • 7.5. Increased Physician Education
  • 7.6. Increased Drug-Treatment Rate
  • 7.7. Improved Guidelines
  • 7.8. Improved Approach to Diagnosis

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
  • 8.3. Clinical Trials by Phase and Trial Status
  • 8.4. Promising Drugs in Clinical Development
  • 8.5. Artificial Fullness Devices
  • 8.6. Promising Deep-Brain Stimulation Devices in Development
  • 8.7. Promising Endoscopic Surgical Devices
  • 8.8. Promising Malabsorption Devices in Development
  • 8.9. Promising Restrictive Devices in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles: Pharmaceutical and Biotech Companies
  • 9.4. Company Profiles: Device Companies

10. Market Outlook

  • 10.1. Global Markets
  • 10.2. United States
  • 10.3. France
  • 10.4. Germany
  • 10.5. Italy
  • 10.6. Spain
  • 10.7. United Kingdom
  • 10.8. Japan
  • 10.9. Brazil
  • 10.10. Canada

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Research Methodology
  • 11.4. Forecasting Methodology
  • 11.5. Physicians, Specialists, and Payers Included in This Study
  • 11.6. About the Authors
  • 11.7. About GlobalData
  • 11.8. Disclaimer

List of Tables

  • Table 1: Target Pathways in the Treatment of Obesity
  • Table 2: Symptoms of Obesity
  • Table 3: The WHO Classification System of Adult Overweight and Obesity According to BMI
  • Table 4: Risk Factors and Comorbidities of Obesity
  • Table 5: 9MM, Age-Adjusted and Crude Prevalence (%) of Obesity, by Sex, Ages ≥ 20 Years, 2008
  • Table 6: JASSO and WHO Classifications of Obesity
  • Table 7: Sources of Epidemiological Data Used for Forecasting the Prevalent Cases of Overweight
  • Table 8: Sources of Epidemiological Data Used for Forecasting the Prevalent Cases of Obesity
  • Table 9: Sources of Epidemiological Data Used for Forecasting the Prevalent Cases of Obesity Class I, Class II, and Class III
  • Table 10: Sources of Epidemiological Data Used for Forecasting the Prevalent Cases of Comorbidities in Overweight/Obese
  • Table 11: 9MM, Prevalent Cases of Overweight, Ages ≥ 18 Years, Both Sexes, N (Millions), 2012-2022
  • Table 12: 9MM, Prevalent Cases of Overweight, by Age, Both Sexes, N (Millions), Row (%), 2012
  • Table 13: 9MM, Prevalent Cases of Overweight, Ages ≥ 18 Years, by Sex, N (Millions), Row (%), 2012
  • Table 14: 9MM, Prevalent Cases of Obesity, Ages ≥ 18 Years, Both Sexes, N (Millions), 2012-2022
  • Table 15: 9MM, Prevalent Cases of Obesity, by Age, Both Sexes, N (Millions), Row (%), 2012
  • Table 16: 9MM, Prevalent Cases of Obesity, Ages ≥ 18 Years, by Sex, N (Millions), Row (%), 2012
  • Table 17: 9MM, Prevalent Cases of Obesity Class I, Ages ≥ 18 Years, Both Sexes, N (Millions), 2012-2022
  • Table 18: 9MM, Prevalent Cases of Obesity Class I, by Age, Both Sexes, N (Millions), Row (%), 2012
  • Table 19: 9MM, Prevalent Cases of Obesity Class I, Ages ≥ 18 Years, by Sex, N (Millions), Row (%), 2012
  • Table 20: 9MM, Prevalent Cases of Obesity Class II, Ages ≥ 18 Years, Both Sexes, N (Millions), 2012-2022
  • Table 21: 9MM, Prevalent Cases of Obesity Class II, by Age, Both Sexes, N (Millions), Row (%), 2012
  • Table 22: 9MM, Prevalent Cases of Obesity Class II, Ages ≥ 18 Years, by Sex, N (Millions), Row (%), 2012
  • Table 23: 9MM, Prevalent Cases of Obesity Class III, Ages ≥ 18 Years, Both Sexes, N (Millions), 2012-2022
  • Table 24: 9MM, Prevalent Cases of Obesity Class III, by Age, Both Sexes, N (Millions), Row (%), 2012
  • Table 25: 9MM, Prevalent Cases of Obesity Class III, Ages ≥ 18 Years, by Sex, N (Millions), Row (%), 2012
  • Table 26: 5MM*, Prevalent Cases of Diagnosed Diabetes among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 and 2022
  • Table 27: 6MM*, Prevalent Cases of Diagnosed Hypertension among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 and 2022
  • Table 28: 4MM, Prevalent Cases of Dyslipidemia* among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012 and 2022
  • Table 29: Treatment Guidelines for Obesity
  • Table 30: Most Prescribed Drugs for Obesity by Class in the Global Markets, 2013
  • Table 31: Classification of Overweight and Obesity by BMI and Waist Circumference, and the Associated Disease Risk
  • Table 32: Brazilian Classification of Overweight and Obesity
  • Table 33: Bariatric Treatment Attributes
  • Table 34: Leading Drug Treatments for Obesity, 2013
  • Table 35: Marketed Obesity Treatment Devices by Type
  • Table 36: Product Profile - Phentermine
  • Table 37: Phentermine SWOT Analysis, 2013
  • Table 38: Global Sales Forecasts ($m) for Phentermine, 2012-2022
  • Table 39: Global Sales Forecasts ($m) for Phentermine + Topiramate, 2012-2022
  • Table 40: Product Profile - Xenical
  • Table 41: Xenical SWOT Analysis, 2013
  • Table 42: Global Sales Forecasts ($m) for Xenical, 2012-2022
  • Table 43: Product Profile - Qsymia
  • Table 44: Qsymia SWOT Analysis, 2013
  • Table 45: Global Sales Forecasts ($m) for Qsymia, 2012-2022
  • Table 46: Product Profile - Belviq
  • Table 47: Belviq SWOT Analysis, 2013
  • Table 48: Global Sales Forecasts ($m) for Belviq, 2012-2022
  • Table 49: Product Profile - Topiramate
  • Table 50: Topiramate SWOT Analysis, 2013
  • Table 51: Product Profile - Oblean
  • Table 52: ObleanSWOT Analysis, 2013
  • Table 53: Global Sales Forecasts ($m) for Oblean, 2012-2022
  • Table 54: Product Profile - End Ball
  • Table 55: End Ball SWOT Analysis
  • Table 56: Product Profile - Obalon
  • Table 57: Obalon SWOT Analysis
  • Table 58: Product Profile - Orbera
  • Table 59: Orbera SWOT Analysis
  • Table 60: Product Profile - Heliosphere
  • Table 61: Heliosphere SWOT Analysis
  • Table 62: Product Profile - ReShape Duo
  • Table 63: ReShape Duo SWOT Analysis
  • Table 64: Product Profile - SatiSphere
  • Table 65: SatiSphere SWOT Analysis
  • Table 66: Product Profile - Spatz
  • Table 67: Spatz SWOT Analysis
  • Table 68: Product Profile - Intraluminal Circular Stapler
  • Table 69: Intraluminal Circular Stapler SWOT Analysis
  • Table 70: Product Profile - OverStitch
  • Table 71: OverStitch SWOT Analysis
  • Table 72: Product Profile - StomaphyX
  • Table 73: StomaphyX SWOT Analysis
  • Table 74: Product Profile - Abiliti
  • Table 75: Abiliti SWOT Analysis
  • Table 76: Product Profile - DIAMOND Tantalus
  • Table 77: DIAMOND Tantalus SWOT Analysis
  • Table 78: Product Profile - EndoBarrier
  • Table 79: EndoBarrier SWOT Analysis
  • Table 80: Product Profile - Vbloc Maestro System
  • Table 81: Vbloc Maestro System SWOT Analysis
  • Table 82: Product Profile - AMI Band
  • Table 83: AMI Band SWOT Analysis
  • Table 84: Product Profile - Bioring
  • Table 85: Bioring SWOT Analysis
  • Table 86: Product Profile - Heliogast
  • Table 87: Heliogast SWOT Analysis
  • Table 88: Product Profile - Lap-Band
  • Table 89: Lap-Band SWOT Analysis
  • Table 90: Product Profile - Midband
  • Table 91: SWOT Analysis
  • Table 92: Product Profile - MiniMizer Extra
  • Table 93: SWOT Analysis
  • Table 94: Product Profile - Swedish/Realize Band
  • Table 95: Swedish/Realize Band SWOT Analysis
  • Table 96: Unmet Need and Opportunity in Obesity
  • Table 97: Endpoint Analysis of Clinical Trials Conducted in Obesity, 2013
  • Table 98: Obesity- Clinical Trials by Phase and Trial Status, 2012
  • Table 99: Obesity - Phase II-III Pipeline, 2013
  • Table 100: Comparison of Therapeutic Classes in Development for Obesity, 2013
  • Table 101: Obesity Treatment Pipeline Devices by Type
  • Table 102: Product Profile - Contrave
  • Table 103: Contrave SWOT Analysis, 2013
  • Table 104: Global Sales Forecasts ($m) for Contrave, 2012-2022
  • Table 105: Product Profile - Victoza
  • Table 106: Victoza SWOT Analysis, 2013
  • Table 107: Global Sales Forecasts ($m) for Victoza, 2012-2022
  • Table 108: Product Profile - Velneperit
  • Table 109: Velneperit SWOT Analysis, 2013
  • Table 110: Global Sales Forecasts ($m) for Velneperit, 2012-2022
  • Table 111: Product Profile - Empatic
  • Table 112: Empatic SWOT Analysis, 2013
  • Table 113: Global Sales Forecasts ($m) for Empatic, 2012-2022
  • Table 114: Obesity - Promising Early-Stage Approaches, 2013
  • Table 115: Product Profile - Full Sense Device
  • Table 116: Full Sense Device SWOT Analysis
  • Table 117: Product Profile - TransPyloric Shuttle
  • Table 118: TransPyloric Shuttle SWOT Analysis
  • Table 119: Product Profile - Deep Brain Stimulation Device
  • Table 120: Deep Brain Stimulation Device SWOT Analysis
  • Table 121: Product Profile - ACE Stapler
  • Table 122: ACE Stapler SWOT Analysis
  • Table 123: Product Profile - RS2 Restore
  • Table 124: RS2 Restore SWOT Analysis
  • Table 125: Product Profile - ValenTx
  • Table 126: ValenTx SWOT Analysis
  • Table 127: Product Profile - AMI B-Band
  • Table 128: AMI B-Band SWOT Analysis
  • Table 129: Product Profile - AMI Basket
  • Table 130: AMI Basket SWOT Analysis
  • Table 131: Product Profile - TERIS
  • Table 132: TERIS SWOT Analysis
  • Table 133: Key Companies in the Obesity Market, 2013
  • Table 134: Orexigen's Disease/Therapy Portfolio Assessment, 2013
  • Table 135: Orexigen Therapeutics SWOT Analysis, 2013
  • Table 136: Novo Nordisk's Disease/Therapy Portfolio Assessment, 2013
  • Table 137: Novo Nordisk SWOT Analysis, 2013
  • Table 138: Takeda's Disease / Therapy Portfolio Assessment, 2013
  • Table 139: Takeda SWOT Analysis, 2013
  • Table 140: Shionogi's Disease/Therapy Portfolio Assessment, 2013
  • Table 141: Shionogi SWOT Analysis, 2013
  • Table 142: Roche Holding's Disease/Therapy Portfolio Assessment, 2013
  • Table 143: Roche Holdings SWOT Analysis, 2013
  • Table 144: Vivus' Disease/Therapy Portfolio Assessment, 2013
  • Table 145: Vivus SWOT Analysis, 2013
  • Table 146: Arena Pharmaceuticals' Disease/Therapy Portfolio Assessment, 2013
  • Table 147: Arena and Eisai SWOT Analysis, 2013
  • Table 148: Company Profile - Allergan
  • Table 149: Allergan SWOT Analysis
  • Table 150: Company Profile - Apollo Endosurgery
  • Table 151: Apollo Endosurgery SWOT Analysis
  • Table 152: Company Profile - Aspire Bariatrics
  • Table 153: Aspire Bariatrics SWOT Analysis
  • Table 154: Company Profile - AMI
  • Table 155: AMI SWOT Analysis
  • Table 156: Company Profile - Bariatric Solutions
  • Table 157: Bariatric Solutions SWOT Analysis
  • Table 158: Company Profile - Baronova
  • Table 159: Baronova SWOT Analysis
  • Table 160: Company Profile - BaroSense
  • Table 161: BaroSense SWOT Analysis
  • Table 162: Company Profile - BFKW
  • Table 163: BFKW SWOT Analysis
  • Table 164: Company Profile - Cousin Biotech
  • Table 165: Cousin Biotech SWOT Analysis
  • Table 166: Company Profile - CR Bard
  • Table 167: CR Bard SWOT Analysis
  • Table 168: Company Profile - Endalis Laboratory
  • Table 169: Endalis Laboratory SWOT Analysis
  • Table 170: Company Profile - EndoGastric Solutions
  • Table 171: EndoGastric Solutions SWOT Analysis
  • Table 172: Company Profile - EndoSphere
  • Table 173: EndoSphere SWOT Analysis
  • Table 174: Company Profile - EnteroMedics
  • Table 175: EnteroMedics SWOT Analysis
  • Table 176: Company Profile - Ethicon Endo-Surgery
  • Table 177: Ethicon Endo-Surgery SWOT Analysis
  • Table 178: Company Profile - GI Dynamics
  • Table 179: GI Dynamics SWOT Analysis
  • Table 180: Company Profile - Helioscopie
  • Table 181: Helioscopie SWOT Analysis
  • Table 182: Company Profile - IntraPace
  • Table 183: IntraPace SWOT Analysis
  • Table 184: Company Profile - Medical Innovation Development
  • Table 185: Medical Innovation Development SWOT Analysis
  • Table 186: Company Profile - MetaCure
  • Table 187: MetaCure SWOT Analysis
  • Table 188: Company Profile - Obalon Therapeutics
  • Table 189: Obalon Therapeutics SWOT Analysis
  • Table 190: Company Profile - ReShape Medical
  • Table 191: ReShape Medical SWOT Analysis
  • Table 192: Company Profile - Spatz Medical
  • Table 193: Spatz Medical SWOT Analysis
  • Table 194: Company Profile - ValenTx
  • Table 195: ValenTx SWOT Analysis
  • Table 196: Global Sales Forecasts ($m) for Obesity, 2012-2022
  • Table 197: Global Obesity Market - Drivers and Barriers, 2012-2012
  • Table 198: Sales Forecasts ($) for Obesity in the United States, 2012-2022
  • Table 199: Key Events Impacting Sales for Obesity in the United States, 2012-2022
  • Table 200: Obesity Market in the United States - Drivers and Barriers, 2012-2022
  • Table 201: Sales Forecasts ($) for Obesity in France, 2012-2022
  • Table 202: Key Events Impacting Sales for Obesity in France, 2012-2022
  • Table 203: Obesity Market in France - Drivers and Barriers, 2012-2022
  • Table 204: Sales Forecasts ($) for Obesity in Germany, 2012-2022
  • Table 205: Key Events Impacting Sales for Obesity in Germany, 2012-2022
  • Table 206: Obesity Market in Germany - Drivers and Barriers, 2012-2022
  • Table 207: Sales Forecasts ($) for Obesity in Italy, 2012-2022
  • Table 208: Key Events Impacting Sales for Obesity in Italy, 2012-2022
  • Table 209: Obesity Market in Italy - Drivers and Barriers, 2012-2022
  • Table 210: Sales Forecasts ($) for Obesity in Spain, 2012-2022
  • Table 211: Key Events Impacting Sales for Obesity in Spain, 2012-2022
  • Table 212: Obesity Market in Spain - Drivers and Barriers, 2012-2022
  • Table 213: Sales Forecasts ($) for Obesity in United Kingdom, 2012-2022
  • Table 214: Key Events Impacting Sales for Obesity in the United Kingdom, 2012-2022
  • Table 215: Obesity Market in the United Kingdom - Drivers and Barriers, 2012-2022
  • Table 216: Sales Forecasts ($) for Obesity in Japan, 2012-2022
  • Table 217: Events Impacting Sales for Obesity in Japan, 2012-2022
  • Table 218: Obesity Market in Japan - Drivers and Barriers, 2012-2022
  • Table 219: Sales Forecasts ($) for Obesity in Brazil, 2012-2022
  • Table 220: Key Events Impacting Sales for Obesity in Brazil, 2012-2022
  • Table 221: Obesity Market in Brazil - Drivers and Barriers, 2012-2022
  • Table 222: Sales Forecasts ($) for Obesity in Canada, 2012-2022
  • Table 223: Events Impacting Sales for Obesity in Canada, 2012-2022
  • Table 224: Obesity Market in Canada - Drivers and Barriers, 2012-2022
  • Table 225: Key Launch Dates
  • Table 226: Key Patent Expiries

List of Figures

  • Figure 1: US, Overweight and Obesity Age-Adjusted Prevalence (%), Ages 20-74 Years, Men, 1960-2010
  • Figure 2: US, Overweight and Obesity Age-Adjusted Prevalence (%), Ages 20-74 Years, Women, 1960-2010
  • Figure 3: France, Overweight and Obesity Prevalence (%), Ages ≥ 15 Years, Men, 1997-2006
  • Figure 4: France, Overweight and Obesity Prevalence (%), Ages ≥ 15 Years, Women, 1997-2006
  • Figure 5: Italy, Overweight and Obesity Prevalence (%), Ages ≥ 18, Men, 1983-2010
  • Figure 6: Italy, Overweight and Obesity Prevalence (%), Ages ≥ 18, Men, 1983-2010
  • Figure 7: UK, Overweight and Obesity Prevalence (%), Ages ≥ 16 Years, Men, 1993-2011
  • Figure 8: UK, Overweight and Obesity Prevalence (%), Ages ≥ 16 Years, Women, 1993-2011
  • Figure 9: Japan, Obesity Prevalence (%), Ages ≥ 20 Years, by Sex, 1976-2006
  • Figure 10: Brazil, Overweight and Obesity Prevalence (%), Ages ≥ 20 Years, Men, 1975-2003
  • Figure 11: Brazil, Overweight and Obesity Prevalence (%), Ages ≥ 20 Years, Women, 1975-2003
  • Figure 12: Canada, Obesity Prevalence (%), Ages ≥ 18 Years, Both Sexes, 1978-2008
  • Figure 13: 9MM, Prevalent Cases of Overweight, Ages ≥ 18 Years, Both Sexes, N (Millions), 2012-2022
  • Figure 14: 9MM, Prevalent Cases of Overweight, by Age, Both Sexes, N (Millions), 2012
  • Figure 15: 9MM, Prevalent Cases of Overweight, Ages ≥ 18 Years, by Sex, N (Millions), 2012
  • Figure 16: 9MM, Overweight Age-Standardized Prevalence (%), Ages ≥ 18 Years, by Sex, 2012
  • Figure 17: 9MM, Prevalent Cases of Obesity, Ages ≥ 18 Years, Both Sexes, N (Millions), 2012-2022
  • Figure 18: 9MM, Prevalent Cases of Obesity, by Age, Both Sexes, N (Millions), 2012
  • Figure 19: 9MM, Prevalent Cases of Obesity, Ages ≥ 18 Years, by Sex, N (Millions), 2012
  • Figure 20: 9MM, Obesity Age-Standardized Prevalence (%), Ages ≥ 18 Years, by Sex, 2012
  • Figure 21: 9MM*, Prevalent Cases of Obesity Class I, Ages ≥ 18 Years, Both Sexes, N (Millions), 2012-2022
  • Figure 22: 9MM*, Prevalent Cases of Obesity Class I, by Age, Both Sexes, N (Millions), 2012
  • Figure 23: 9MM*, Prevalent Cases of Obesity Class I, Ages ≥ 18 Years, by Sex, N (Millions), 2012
  • Figure 24: 9MM*, Obesity Class I Age-Standardized Prevalence (%), Ages ≥ 18 Years, by Sex, 2012
  • Figure 25: 9MM*, Prevalent Cases of Obesity Class II, Ages ≥ 18 Years, Both Sexes, N (Millions), 2012-2022
  • Figure 26: 9MM*, Prevalent Cases of Obesity Class II, by Age, Both Sexes, N (Millions), 2012
  • Figure 27: 9MM*, Prevalent Cases of Obesity Class II, Ages ≥ 18 Years, by Sex, N (Millions), 2012
  • Figure 28: 9MM*, Age-Standardized Prevalence (%) of Obesity Class II, Ages ≥ 18 Years, by Sex, 2012
  • Figure 29: 9MM*, Prevalent Cases of Obesity Class III, Ages ≥ 18 Years, Both Sexes, N (Millions), 2012-2022
  • Figure 30: 9MM*, Prevalent Cases of Obesity Class III, by Age, Both Sexes, N (Millions), 2012
  • Figure 31: 9MM*, Prevalent Cases of Obesity Class III, Ages ≥ 18 Years, by Sex, N (Millions), 2012
  • Figure 32: 9MM*, Obesity Class III Age-Standardized Prevalence (%), Ages ≥ 18 Years, by Sex, 2012
  • Figure 33: 5MM*, Prevalent Cases of Diagnosed Diabetes among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012
  • Figure 34: 6MM*, Prevalent Cases of Diagnosed Hypertension among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012
  • Figure 35: 4MM*, Prevalent Cases of Dyslipidemia** among Adults with Overweight/Obesity, Both Sexes, N (Millions), 2012
  • Figure 36: Treatment Algorithm for Obesity
  • Figure 37: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in the United States, 2012-2022
  • Figure 38: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in France, 2012-2022
  • Figure 39: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Germany, 2012-2022
  • Figure 40: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Italy, 2012-2022
  • Figure 41: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Spain, 2012-2022
  • Figure 42: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in the United Kingdom, 2012-2022
  • Figure 43: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Japan, 2012-2022
  • Figure 44: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Brazil, 2012-2022
  • Figure 45: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Canada, 2012-2022
  • Figure 46: Obesity Therapeutics - Clinical Trials by Country, 2012
  • Figure 47: Competitive Assessment of Late-Stage Pipeline Agents in Obesity, 2012-2022
  • Figure 48: Company Portfolio Gap Analysis in Obesity, 2012-2022
  • Figure 49: Global Sales for Obesity by Region, 2012-2022
  • Figure 50: Sales for Obesity in the United States by Drug Class, 2012-2022
  • Figure 51: Sales for Obesity in France by Drug Class, 2012-2022
  • Figure 52: Sales for Obesity in Germany by Drug Class, 2012-2022
  • Figure 53: Sales for Obesity in Italy by Drug Class, 2012-2022
  • Figure 54: Sales for Obesity in Spain by Drug Class, 2012-2022
  • Figure 55: Sales for Obesity in the United Kingdom by Drug Class, 2012-2022
  • Figure 56: Sales for Obesity in Japan by Drug Class, 2012-2022
  • Figure 57: Sales for Obesity in Brazil by Drug Class, 2012-2022
  • Figure 58: Sales for Obesity in Canada by Drug Class, 2012-2022
Back to Top